Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Total Non-Current Liabilities data on file, last reported at $95.2 million in Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 72.95% year-over-year to $95.2 million; the TTM figure through Dec 2025 stood at $95.2 million (down 72.95% YoY), while the FY2025 annual figure was $95.2 million, down 72.95% from the prior year.
• Total Non-Current Liabilities eased to $95.2 million in Q4 2025, from $268.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $388.9 million in Q2 2025 and bottomed at $262860.0 in Q1 2021.
• A 5-year average of $276.2 million and a median of $323.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 143102.85% — and 2025, when it sank 72.95%.
• Year by year, Total Non-Current Liabilities stood at $124.3 million in 2021, then soared by 132.36% to $288.9 million in 2022, then jumped by 31.83% to $380.8 million in 2023, then retreated by 7.59% to $351.9 million in 2024, then sank by 72.95% to $95.2 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $95.2 million (Q4 2025), $268.1 million (Q3 2025), and $388.9 million (Q2 2025), per Business Quant data.

Peer Comparison